High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness
Open accessAbstract
Rationale Nicotinic acetylcholine receptors (nAChRs) are a critical component of the cholinergic system of neurotransmission in the brain that modulates important physiological processes such as reward, cognition, and mood. Abnormalities in this system are accordingly implicated in multiple psychiatric illnesses, including addiction, schizophrenia, and mood disorders. There is significantly increased tobacco use, and therefore nicotine intake, in patient populations, and pharmacological agents that act on various nicotinic receptor subtypes ameliorate clinical features of these disorders. Better understanding of the molecular mechanisms underlying cholinergic dysfunction in psychiatric disease will permit more targeted design of novel therapeutic agents.Results The objective of this review is to describe the multiple cellular pathways through which chronic nicotine exposure regulates nAChR expression, and to juxtapose these mechanisms with evidence for altered expression of high-affinity nAChRs in human psychiatric illness. Here, we summarize multiple studies from pre-clinical animal models to human in vivo imaging and post-mortem experiments demonstrating changes in nAChR regulation and expression in psychiatric illness.Conclusions We conclude that a mechanistic explanation of nAChR abnormalities in psychiatric illness will arise from a fuller understanding of normal nAChR trafficking, along with the detailed study of human tissue, perhaps using novel biotechnological advances, such as induced pluripotent stem cells.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Impairments to cholinergic signaling in the adult human brain have been linked to psychiatric disorders in adult patients, including schizophrenia, anxiety, and depression.
“Impairments to cholinergic signaling in the adult human brain have been linked to psychiatric disorders in adult patients, including schizophrenia, anxiety, and depression [101–103].”
From Adolescent nicotine exposure and persistent neurocircuitry changes: unveiling lifelong psychiatric risks (2025) · cites this paper as [101]
The Mood disorders section (page unavailable) explicitly links impaired cholinergic signaling to schizophrenia and depression, drawing on human imaging studies. The passages do not establish the claimed link for anxiety; a search for “anxiety” found no relevant passage. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 70 · Cited by 38
- Authors
- Lewis, A. S., & Picciotto, M. R.
- Affiliations
- Yale University (US)
- Corresponding author
- Picciotto, Marina R.
- Venue
- Psychopharmacology
- Published
- 2013-04-28
- Volume
- 229
- Issue
- 3
- Pages
- 477-485
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC3766461
- OpenAlex
- W2034357979
- Cited by
- 38
- References
- 70
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 4 · 2018: 2 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 3
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (MH077681, R01MH077681, T32MH019961, R25MH071584)
- National Institute on Drug Abuse (R01DA014241, DA014241, P50DA033945, R37DA014241, DA033945)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
- Keywords
- nicotinic acetylcholine receptors, receptor trafficking, cholinergic dysfunction, mental illness, chronic nicotine exposure, schizophrenia, mood disorders, addiction, postmortem brain, in vivo imaging, induced pluripotent stem cells
- MeSH terms
- Animals, Mental Disorders, Brain, Cognition, Humans, Synaptic Transmission, Nicotine, Receptors, Nicotinic, Reward, Up-Regulation, Protein Transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review